Leuprorelin Endomedica

Leuprorelin acetate, the active ingredient in Leuprorelin Endomedica, is a gonadotropin‑releasing hormone (GnRH) agonist presented as an injection for subcutaneous use. It is used to suppress sex hormone production in conditions such as prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

GNH USA supplies Leuprorelin Endomedica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Leuprorelin Endomedica is a GnRH agonist used in hormone‑dependent disease pathways. It provides medical hormone suppression for several recognized indications.

- Prostate cancer: lowers testosterone to achieve medical castration and delay disease progression. - Endometriosis: reduces estrogen levels to alleviate pelvic pain and lesion growth. - Uterine fibroids: suppresses ovarian hormones to shrink fibroid size and improve bleeding. - Central precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis in children. - Breast cancer (selected cases): diminishes estrogen exposure as part of hormonal therapy protocols.

Leuprorelin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: pain, redness, or swelling at the injection site. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Mood changes: irritability or depressive symptoms. - Decreased libido: reduced sexual desire.

Serious or Rare Side Effects: - Bone mineral density loss: increased risk of osteoporosis and fractures. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe allergic reaction: anaphylaxis or angioedema. - Pituitary apoplexy: sudden hemorrhage within the pituitary gland. - Adrenal insufficiency: impaired cortisol production requiring monitoring.

Leuprorelin therapy requires careful monitoring and patient education.

- Monitor bone health: assess risk of osteoporosis during long‑term use. - Cardiovascular assessment: evaluate baseline cardiac risk before initiating therapy. - Hormone level checks: regularly measure testosterone or estrogen to ensure adequate suppression. - Drug interactions: review concomitant medications that may affect hormone balance. - Pregnancy avoidance: ensure effective contraception for women of child‑bearing potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuprorelin can interact with other medicines that influence hormone pathways or cardiovascular function.

Major Interactions (Avoid): - GnRH antagonists: concurrent use may blunt therapeutic effect. - Hormone replacement therapy: may counteract hormone suppression. - Strong CYP3A4 inducers: could reduce drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants: may increase risk of mood changes. - Anticoagulants: monitor for altered bleeding risk. - Diuretics: watch electrolyte balance, especially potassium.